Ketamine’s therapeutic effects in status epilepticus may, in part, involve brain-derived neurotrophic factor (BDNF) signaling via TrkB activation—a pathway known to mediate Ketamine’s antidepressant effects and exert neuroprotective roles in epilepsy through the modulation of synaptic plasticity and neuronal survival [63]. The gene discussed is BDNF; the disease is status epilepticus.